Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a company overview at the H.C. Wainwright Annual Global Investment Conference....
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with this Read more ...
G1 Therapeutics, Inc. (GTHX) Q2 2019 Earnings Conference Call August 07, 2019 16:30 P.M. ET Company Participants Jeff Macdonald - Head, Investor & Public Relations Mark Velleca - CEO Rajesh Malik - CMO and SVP, R&D Jennifer Moses - CFO Conference Call Participants ...
Gainers : Corindus Vascular Robotics (NYSEMKT: CVRS ) +76% . Vitamin Shoppe (NYSE: VSI ) +41% . Avedro (NASDAQ: AVDR ) +36% . G1 Therapeutics (NASDAQ: GTHX ) +27% . Alpha and Omega Semiconductor (NASDAQ: AOSL ) +22% . Carvana (NYSE: CVNA ) +21% . Roku (NASDAQ: ROKU ) +20% ...
G1 Therapeutics ( GTHX +26% ) is up almost 20% higher volume following its Q2 report released after the close yesterday. Highlights: More news on: G1 Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
G1 Therapeutics (NASDAQ: GTHX ): Q2 GAAP EPS of -$0.82 misses by $0.10 . More news on: G1 Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- FDA grants Breakthrough Therapy Designation for trilaciclib based on myelopreservation data in small cell lung cancer patients - First clinical data on oral SERD G1T48 in breast cancer to be presented at ESMO 2019 Congress - Management to host webcast and confer...
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in two investor conferences in August 2019. The company will meet with investors at the 2019 BTIG Bi...
RESEARCH TRIANGLE PARK, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2019 on Wednesday, A...
RESEARCH TRIANGLE PARK, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief Business Officer. In this role, Mr. Avagliano will serve as a member of the G1 executive team a...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...